
In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery in localized, high/intermediate-risk GIST patients. Interim analysis results were published in 2015 upon recommendation from an independent data review committee.
Like
Save
Share